| | Variables | Training cohort | Internal test cohort | External test cohort | | Non-LM | LM | Non-LM | LM | Non-LM | LM | | Total | N = 34,775 | N = 1,780 | N = 14,853 | N = 814 | N = 468 | N = 24 |
| | Age | | Mean (SD) | 59.6 (12.4) | 61.3 (11.1) | 59.8 (12.3) | 61.1 (10.8) | 59.5 (10.8) | 60.0 (9.07) |
| | Sex | | Female | 13,622 (37.3%) | 514 (28.9%) | 5,524 (37.2%) | 232 (28.5%) | 173 (37.0%) | 4 (16.7%) | | Male | 22,933 (62.7%) | 1,266 (71.1%) | 9,329 (62.8%) | 582 (71.5%) | 295 (63.0%) | 20 (83.3%) |
| | Laterality | | Left | 17,982 (49.2%) | 889 (49.9%) | 7,302 (49.2%) | 429 (52.7%) | 248 (53.0%) | 12 (50.0%) | | Right | 18,573 (50.8%) | 891 (50.1%) | 7,551 (50.8%) | 385 (47.3%) | 220 (47.0%) | 12 (50.0%) |
| | Race | | Asian | 2,163 (5.9%) | 131 (7.4%) | 908 (6.1%) | 62 (7.6%) | 468 (100%) | 24 (100%) | | Black | 3,986 (10.9%) | 134 (7.5%) | 1,671 (11.3%) | 44 (5.4%) | 0 (0%) | 0 (0%) | | Others | 720 (2.0%) | 27 (1.5%) | 299 (2.0%) | 12 (1.5%) | 0 (0%) | 0 (0%) | | White | 29,686 (81.2%) | 1,488 (83.6%) | 11,975 (80.6%) | 696 (85.5%) | 0 (0%) | 0 (0%) |
| | T_stage | | T1 | 24,358 (66.6%) | 190 (10.7%) | 10,281 (69.2%) | 84 (10.3%) | 393 (84.0%) | 8 (33.3%) | | T2 | 3,920 (10.7%) | 310 (17.4%) | 1,550 (10.4%) | 140 (17.2%) | 29 (6.2%) | 7 (29.2%) | | T3 | 7,580 (20.7%) | 1,012 (56.9%) | 2,855 (19.2%) | 476 (58.5%) | 42 (9.0%) | 6 (25.0%) | | T4 | 697 (1.9%) | 268 (15.1%) | 167 (1.1%) | 114 (14.0%) | 4 (0.9%) | 3 (12.5%) |
| | N_stage | | N0 | 34,928 (95.5%) | 1,171 (65.8%) | 14,437 (97.2%) | 557 (68.4%) | 452 (96.6%) | 18 (75.0%) | | N1 | 1,627 (4.5%) | 609 (34.2%) | 416 (2.8%) | 257 (31.6%) | 16 (3.4%) | 6 (25.0%) |
| | Tumor_size | | Mean (SD) | 53.6 (37.4) | 102 (48.9) | 51.1 (34.4) | 101 (55.6) | 42.9 (22.0) | 68.6 (27.0) |
| | Histology | | 8120 | 126 (0.3%) | 24 (1.3%) | 45 (0.3%) | 11 (1.4%) | 0 (0%) | 0 (0%) | | 8255 | 926 (2.5%) | 80 (4.5%) | 373 (2.5%) | 45 (5.5%) | 0 (0%) | 0 (0%) | | 8260 | 4,202 (11.5%) | 70 (3.9%) | 1,777 (12.0%) | 28 (3.4%) | 22 (4.7%) | 0 (0%) | | 8310 | 24,731 (67.7%) | 1,146 (64.4%) | 10,164 (68.4%) | 535 (65.7%) | 427 (91.2%) | 21 (87.5%) | | 8312 | 4,060 (11.1%) | 269 (15.1%) | 1,544 (10.4%) | 113 (13.9%) | 16 (3.4%) | 3 (12.5%) | | 8317 | 1,550 (4.2%) | 14 (0.8%) | 654 (4.4%) | 6 (0.7%) | 0 (0%) | 0 (0%) | | Others | 960 (2.6%) | 177 (9.9%) | 296 (2.0%) | 76 (9.3%) | 3 (0.6%) | 0 (0%) |
| | Grade | | I | 4,111 (11.2%) | 42 (2.4%) | 1,724 (11.6%) | 19 (2.3%) | 69 (14.7%) | 0 (0%) | | II | 18,545 (50.7%) | 330 (18.5%) | 7,799 (52.5%) | 146 (17.9%) | 266 (56.8%) | 5 (20.8%) | | III | 10,779 (29.5%) | 747 (42.0%) | 4,260 (28.7%) | 324 (39.8%) | 109 (23.3%) | 12 (50.0%) | | IV | 3,120 (8.5%) | 661 (37.1%) | 1,070 (7.2%) | 325 (39.9%) | 24 (5.1%) | 7 (29.2%) |
|
|
LM, lung metastasis; 8120, transitional cell carcinoma; 8255, adenocarcinoma with mixed subtypes; 8260, papillary adenocarcinoma; 8310, clear cell adenocarcinoma; 8312, renal cell carcinoma; 8317, chromophobe renal carcinoma.
|
